BACKGROUND & AIMS-Gastric cancer (GC) is a heterogeneous disease comprising multiple subtypes that each have distinct biological properties and effects in patients. We sought to identify new, intrinsic subtypes of GC by gene expression analysis of a large panel of GC cell lines. We tested if these subtypes might be associated with differences patient survival times and responses to various standard-of-care cytotoxic drugs.
Introduction
Gastric adenocarcinoma (gastric cancer, GC) is the second leading cause of global cancer mortality and 4 th most common cancer worldwide 1 . Most GC patients present with late stage disease with an overall 5-year survival of about 20% 2 . A wealth of clinical, molecular, and pathological data suggests that GC is a heterogeneous disease. Objective response rates to conventional chemotherapeutic regimens range from 20-40% 3 , indicating that individual GCs can exhibit a range of responses when treated identically. Canonical oncogenic pathways such as E2F, K-RAS, p53, and Wnt/β-catenin signalling are also known to be deregulated with varying frequencies in GC 4, 5 , suggesting a high degree of molecular heterogeneity. However, despite evidence that GCs can exhibit striking inter-individual differences in disease aggressiveness 6 , histopathologic features 7 , and responses to therapy 8 , most GC patients today are managed alike with a "one size fits all" approach resulting in markedly diverse clinical outcomes. Approaches capable of classifying heterogeneous populations of GC patients into biologically and clinically homogenous subgroups are thus urgently required, such that GC patient prognoses can be accurately predicted, and clinical decisions made based on the underlying biology of each subgroup.
Reflecting this urgency, several classification systems for GC have been reported over the decades. In 1965, Lauren described two main subtypes of GC, intestinal and diffuse, on the basis of microscopic features observed in gastric tumors 7 . Since then, several other GC histopathological classifications have since been developed, such as the WHO 9 , Ming 10 , and Goseki 11 systems, and more recently, molecular classifications based on immunohistochemistry, gene expression profiles [12] [13] [14] [15] , and proteomic technologies 16 . However, to date, none of these GC classification systems been shown to provide reliable independent prognostic information, nor have they been able to suggest specific treatment options for patients.
Most previously-described GC classification systems have principally focused on the characterization of primary tumors, which are known to contain many distinct cell types including tumor cells, fibroblastic/desmoplastic stroma, blood vessels, and immune cells. Given this high level of tissue complexity, we reasoned that subtle variations in these diverse cell types, both across and within-tumors, could cause differences in interpretation between observers, and ultimately pose difficulties for standardization across different centres. In this study, we pursued an alternative strategy where we initially focused not on primary GCs, but on a diverse panel of GC cell lines. We hypothesized that since cancer cell lines are devoid of other cell types besides cancer cells, any genomic differences detected in cell lines should be by nature tumor-centric and thereby "intrinsic" to the underlying biology of the GC cancer cell. Investigating a large panel of GC cell lines, we identified a genomic expression signature clearly defining two major intrinsic subgroups of GC. Importantly, we validated these intrinsic subgroups in primary tumors from 4 independent GC cohorts. The, intrinsic subtypes proved capable of providing independent prognostic information. In vitro and in vivo evidence also suggests that GCs belonging to different intrinsic subtypes may respond differently to various standard-of-care chemotherapies.
MATERIALS AND METHODS

GC Cell Lines
GC cell lines were obtained from commercial sources or collaborators and cultured as recommended (Supplementary Info). Cell proliferation assays were performed using a tetrazolium compound-based colorimetric method (Supplementary Methods).
Patient Cohorts and Clinical Characteristics
Four independent patient cohorts were analyzed (n=521). Cohort 1 (SG): 200 patients, National Cancer Centre Singapore, Singapore; Cohort 2 (AU): 70 patients, Peter MacCallum Cancer Centre, Australia; Cohort 3 (YG): 65 patients, Yonsei University, South Korea; Cohort 4 (TMA): 186 patients, National Healthcare Group, Singapore. Primary tumors were collected from institutional tissue repositories and pathology archives with approvals from Research Ethics Review Committees and signed patient informed consent. There was no pre-specified sample size calculation since this is a hypothesis generating discovery study. Clinical characteristics of the four cohorts are in accordance with REMARK guidelines 17 and presented in Table 1 . Clinical information was available for all patients except 3 patients in the SG cohort. Cohorts 1-3 (SG/AU/YG) comprise gene expression profiles of primary GCs, while cohort 4 (TMA) comprises tumor sections on a tissue microarray.
Gene Expression Profiling (GC Cell lines and Primary Tumors)
GC cell lines and patient cohorts 1 and 2 were profiled using Affymetrix Human Genome U133 plus Genechips (HG-U133 Plus 2.0, Affymetrix). Patient cohort 3 was profiled using Illumina Human-6 v2 Expression Beadchips. Primary microarray data is available in the GEO database (GSE 15460 and GSE13861).
Histology and Immunohistochemistry
Two independent pathologists (LKH, WWK) performed central pathologic review on cohort 1 samples blinded to the genomic classification. Immunohistochemical studies using LGALS4 and CDH17 antibodies were performed on a tissue microarray of 186 GC patients (cohort 4), and staining intensities determined by a pathologist blinded to the clinical data (MST). Photomicrographs, details of staining patterns and grading scales are provided in the Supplementary Information.
Bioinformatics and Statistical Analysis
Bioinformatic analyses were performed using R. Raw affymetrix datasets were preprocessed with quantile normalization using RMA (package Affy). We filtered the Gastric cancer cell line using the nsFilter function from the Genefilter package on Bioconductor. The R package LIMMA was used for feature selection. Enrichment of functional annotations in the gene expression data were performed using EASE software (http://apps1.niaid.nih.gov/david/). Statistical significance was determined using the Fisher exact score and EASE score. For patient cohorts, preprocessing of cohort 1 and 2 (Affymetrix) was performed with Refplus while preprocessing of cohort 3 (Illumina) was performed with quantile normalization and the average signal intensity used for summarization. Nearest Template Prediction 18, 19 was performed using Genepattern 20 . The R package e1071 was used for support vector machine (SVM) learning and classification. Correlation with clinico-pathologic parameters and survival analysis were performed using SPSS software (version 16, Chicago). Survival curves were estimated using the KaplanMeier method and the duration of survival was measured from the date of surgery to date of death or last follow-up visit. Cancer-specific survival (CSS) was used as the outcome metric, with deaths due to cancer was regarded as an event. Patients who are still alive, died from other causes or lost to follow-up at time of analysis were censored at their last date of follow up. Univariable and multivariable survival analyses were performed using the Cox proportional hazards regression model. The test of interaction between the genomic subtypes and therapy was performed with the null hypothesis of treatment equivalence within the subtypes and the alternative hypothesis was of differential treatment efficacy in the subtypes 21 . Two-sided p-values less than 0.05 were considered statistically significant.
Further details of bioinformatics and statistical analyses are provided in the Supplementary Information.
RESULTS
Genomic Analysis of GC Cell Lines Reveals Two Major Intrinsic Subclasses
We performed gene expression profiling for a panel of 37 GC cell lines. To identify pervasive and thereby "intrinsic" gene expression differences across the cell lines, we analyzed the expression data using four different unsupervised and unbiased clustering techniques (hierarchical clustering, silhouette plot (SP) analysis 22 , nonnegative matrix factorization (NMF) 23 , and principal components analysis (PCA)). Two major intrinsic subtypes were identified by hierarchical clustering ( Figure 1A ). The robustness of the subtypes was further verified by SP, NMF, and PCA analysis ( Figure 1B and Supplementary Figure S1 ). For reasons that will become apparent in later sections, we will henceforth refer to these two intrinsic subtypes as Genomic intestinal (G-INT) and Genomic Diffuse (G-DIF).
The Intrinsic Subtypes are Associated with Highly Distinctive Gene Expression Patterns
To analyze gene expression differences between the intrinsic subtypes, we used LIMMA (Linear models for microarray data) 24 , a modified t-test incorporating the Benjamini Hochberg multiple correction technique. We identified a genomic signature of 171 genes distinguishing the G-INT and G-DIF intrinsic subtypes (FDR<0.002; Figure 1C and Supplementary Table S1 ). We attempted to refine this signature by searching for potentially redundant features among the 171 gene set. Comparing the correlation coefficients of the 171 genes to one another, we found that only 2 of the 171 genes exceeded a pre-defined correlation threshold of 0.88. Given this lack of redundancy, we performed further analysis using the entire 171 gene set. Using Expression Analysis Systematic Explorer (EASE) (http://david.abcc.ncifcrf.gov/ease/ease.jsp), we identified enriched biological themes within genes expressed in either subtype Genes up-regulated in the G-INT subtype were related to carbohydrate and protein metabolism (FUT2) and cell adhesion (LGALS4, CDH17), while cell proliferation (AURKB) and fatty acid metabolism (ELOVL5) functional annotations were enriched in the G-DIF subtype (within system FDR < 0.01, Supplementary Methods and Supplementary Table S2 ). The two intrinsic subtypes, G-INT and G-DIF, are thus associated with highly distinctive gene expression patterns and biological pathways.
The Intrinsic Subtypes are Recurrently Observed in Primary Tumors
We mapped the intrinsic 171-gene genomic signature onto primary tumors in two independent cohorts of GC patients (SG and AU), collectively totaling 270 patients. We used 2 classification algorithms (Nearest Template Prediction and a support vector machine classifier). Concordance between the 2 classification systems (SVM and NTP) was 94-96% in the SG and AU cohorts with 88% of samples identified by NTP at an FDR of < 0.05. These results suggest the 171 gene set can robustly classify primary tumors into G-INT and G-DIF sub-classes. Due to its methodological simplicity and applicability to single samples without requiring a corresponding training dataset 19 , the NTP classifications were used for subsequent analyses. Specifically, 114 samples in the SG cohort and 38 samples in the AU cohort were classified as G-INT (Figures 2A&B) (Supplementary Table S3 ).
The Intrinsic Subtypes are Partially Associated with Lauren's Histopathologic Classification
We next investigated their associations with clinical-pathologic parameters. The intrinsic subtypes were found to be significantly associated with Lauren's intestinal and diffuse subtypes respectively in the SG (p=0.002) and AU cohorts (p=0.003), hence their name (G-INT and G-DIF). Besides Lauren's, the intrinsic subtypes were also related to tumor grade (Supplementary Table S3 ).
Although we named the intrinsic subtypes G-INT and G-DIF due to their associations with Lauren's histopathology, it is worth noting that the overall concordance between the intrinsic genomic subtypes and Lauren's histopathology was only 64%. Thus, the two classifications should more appropriately be regarded as related but distinct. Specifically, 91 of 134 Lauren's intestinal cases were classified at G-INT, and 64 of 106 Lauren's diffuse cases were classified as G-DIF (Figures 2A&B). These discrepancies are unlikely to be due to inter-pathologist differences alone, as pathologic review in the SG cohort had been performed by 2 independent pathologists blinded to the genomic classification (Representative H&E slides of discordant tumors are also presented in figures 2C & 2D). Rather, it is possible that the intrinsic genomic signature may capture salient features of the tumor that are less obvious to discern by light microscopy.
The Intrinsic Subtypes are Independently Prognostic of Patient Survival
We next asked if the intrinsic subtypes could be used to define patient subgroups exhibiting differences in survival outcomes. Using cancer-specific survival as the outcome metric, patients with G-DIF cancers had worse survival outcomes compared to patients with G-INT tumors in the SG and AU cohorts (cohort 1: HR 1.78, 95%CI: 1.19-2.64, p=0.004; cohort 2: HR 1.73, 95%CI: 0.92-3.26, p=0.09) and also in a combined analysis (HR: 1.79, 95% CI: 1.28-2.51, p=0.001, Figure 3A) . In contrast, Lauren's classification was not prognostic (p=0.23). Further supporting the prognostic relevance of the intrinsic subtypes, in discordant cases, patients with G-INT but diffuse type cancers exhibited superior survival compared to patients with G-DIF but intestinal type cancers (HR 1.83, 95%CI: 1.02-3.30, p=0.04, Figure  3B ).
In a multivariate analysis (Table 2) , the intrinsic subtypes remained prognostic (p<0.001) even after accounting for other interacting factors such as Lauren's classes and grade. The intrinsic subtypes were also prognostic after accounting for other variables that were also prognostic in univariate analysis (stage, margin status and gender) (p=0.005).
The Intrinsic Subtypes are Prognostic in an Independent Patient Cohort Profiled by a Different Microarray Platform
To further determine the general applicability of the intrinsic subclasses, we then applied the intrinsic genomic signature onto a third GC patient cohort (YG) profiled on a different microarray platform (Illumina Human-6 v2 Expression Beadchip). Of the 65 patients, 35 were classified as G-INT by NTP (heatmap provided in Supplementary Figure S3A) . Similar to the SG and AU cohorts, patients with G-INT tumors had superior overall survival compared to patients with G-DIF tumors in the YG cohort (HR 3.3, 95%CI: 1.03-10.53, p=0.04) (Supplementary Figure S3B) , while Lauren's classes was not prognostic (p=0.23).
G-INT Patients Identified by Immunohistochemical Markers Exhibit Improved Survival Outcomes
To assess if a panel of immunohistochemical markers might also be used to identify the intrinsic subtypes and its relation to survival outcomes, we then analyzed an independent tissue microarray (TMA) cohort (cohort 4) of 186 GC patients. We selected 2 G-INT markers (LGALS4 and CDH17) meeting the criteria of high gene expression in G-INT cell lines and tumors, and for which commercial immunohistochemical markers were available. We classified the TMA tumors based on their intensity of LGALS4 and CDH17 staining (CDH17 (> 1+) and LGALS4 (>2+)), using intensity cutoffs determined by a pathologist blinded to the clinical data (see Supplementary Information). To confidently distinguish between G-INT and G-DIF cancers, we specifically compared the 2-marker positive group Figure S4) , while Lauren was once again not prognostic (p=0.33).
The Intrinsic Subtypes Exhibit Distinct in vitro Responses to Chemotherapy
Of the 37 cell lines, 28 cell lines (11 G-INT and 17 G-DIF) had growth characteristics suitable for in vitro drug sensitivity testing (see Supplementary Methods). 5-FU, oxaliplatin and cisplatin are drugs presently employed in the adjuvant and 1 st line palliative treatment of GC. We treated the 28 cell lines with increasing concentrations of these drugs. G-INT cell lines were significantly more sensitive to 5-FU (p=0.04) and oxaliplatin (p=0.02) in vitro, while G-DIF cell lines were more sensitive to cisplatin (p=0.03) (Figure 4 , see legend for mean drug concentrations). The in vitro dosages used are comparable to therapeutic ranges observed in human patients based on pharmacokinetic analysis [25] [26] [27] (grey lines in Figure 4) . These results point to differential in vitro sensitivities of G-INT cell lines to 5-FU and oxaliplatin, and G-DIF cell lines to cisplatin.
G-INT Patients may Derive Differential Benefit from 5-FU Treatment
Information regarding use of adjuvant 5 Fluorouracil chemoradiation were available from 2 gene expression cohorts (1 &2) and the TMA cohort (cohort 4). Decisions regarding adjuvant therapy in these cohorts were based upon existing knowledge at the point of diagnosis, patient's general health status, risk factors for relapse especially disease stage, treatment related toxicities and patient preference.
Patients with advanced stage disease were more likely to receive adjuvant treatment (p=0.03), however no significant differences were observed in prescribing 5-FU therapy between the intrinsic subtypes either across all stages (p=0.27) or within each stage (p~0.4-0.8) (Supplementary Table S3 ). We performed a statistical test for interaction that was specifically adjusted for stage, to evaluate if the intrinsic subtypes might exhibit differential benefit with 5-FU chemoradiation in our patient cohorts.
We observed a significant interaction between the intrinsic subtypes and benefit with 5-FU based chemoradiation ( Table 3 ), suggesting that patients with G-INT tumors may derive differential benefit from adjuvant 5-FU based therapy. Specifically, the test for interaction by Cox proportional hazards regression was p=0.002 (combined analysis), gene expression (p=0.03) and TMA cohorts (p=0.02). The stage adjusted hazard ratio of death due to cancer for surgery alone compared to adjuvant 5-FU therapy was 1.68 (p=0.06 for G-INT tumors and 0.90 (p=0.67) for G-DIF tumors. Table 3 presents the interactions for the combined analysis, while the gene expression and TMA cohorts are separately presented in Supplementary Table 4 .
DISCUSSION
In this study, we report the discovery of two genomic subtypes of GC using profiles initially derived from GC cell lines. Since cancer cell lines are devoid of stroma, vasculature and immune cells, we reasoned that comparing signatures between cell lines would be more likely to reflect intrinsic differences between tumor cells, minimizing potentially confounding effects from neighboring non-cancer tissues. The validity of the cell line based approach is supported by similar studies in other solid tumors 28, 29 , where major patterns of tumor heterogeneity have also been shown to be recapitulated by cell lines. We acknowledge that this approach does have caveats -for example, it may miss rare subtypes represented by only one or two lines, or subtypes for which it is difficult to derive immortalized cell lines. The use of cell lines is also unlikely to fully recapitulate the biology of tumor/microenvironment interactions, which can also influence disease prognosis and treatment response. Nevertheless, we believe the intrinsic subtypes discovered in this study represents an important first step in establishing a basic foundational taxonomy of GC, one to which additional layers of genomic complexity can be subsequently added.
One notable aspect of our study was that unlike previous comparative molecular studies for GC 30, 31 , we chose to use unsupervised approaches for subclass discovery. We did so because a) the major distinctions in the molecular heterogeneity of GC might be unrelated to presently known classification systems or phenotypes, and b) using current classification systems, reproducibility among pathologists is only about 70% 32, 33 and we were concerned that this lack of inter-observer concordance might compromise supervised analysis. Testing several different prediction algorithms, we confirmed that the intrinsic subtypes exhibited stable and reproducible classification performance in cell lines and primary tumors, thus demonstrating that the subtypes are statistically robust. Using a strict filtering criteria (FDR<0.002), we then identified a genomic classifier of 171 genes exhibiting differential regulation between the subtypes. Biological curation of the classifier confirmed that the intrinsic subtypes are associated with very different gene expression features, cellular processes and biological pathways. Taken collectively, these finding are consistent with the intrinsic subtypes being very distinct and possibly representing distinct lineages.
The clinical relevance of the intrinsic subclasses is supported by the finding that it can act as an independent predictor of clinical survival in multiple patient cohorts, even after controlling for tumor stage. In this regard, it is interesting to contrast the intrinsic subclasses against Lauren's histological subtypes (intestinal and diffuse), to which the intrinsic classes are partially associated. Intestinal cancers are classically characterized by glandular differentiation on a background of gastric atrophy or intestinal metaplasia, while diffuse cancers typically appear as rows of single mononuclear "signet ring" cells with little cell adhesion. These apparently distinct features, however, are not always discernable in clinical samples where inter-observer variation and unclassifiable or "mixed" subtypes are not uncommonly reported. In our study, patients stratified by Lauren's histopathology did not exhibit significantly different survival outcomes, while patients discordant between the intrinsic subclasses and Lauren's exhibited survival patterns that support the intrinsic genomic taxonomy. Our data thus suggests that the intrinsic subclasses can provide information about the predominant lineage in GC samples that may not be precisely distinguished by morphology, and that this information is clinically relevant.
Besides gene expression, we also employed two genes in the classifier (LGALS4 and L1-Cadherin (CDH17)) as immunohistochemical markers for the G-INT intrinsic subtype.
LGALS4 and CDH17 have been previously reported to be differentially regulated across subsets of gastric tumors 14 and cell line 34 , and expressed in intestinal metaplasia 35, 36 . CDH17 was recently reported as a prognostic factor in early-stage GC 37 , a marker of poor prognosis in another study 36 , and a potential therapeutic target in experimental models 38 . In our study, we specifically chose to compare the 2-marker positive group to the 2-marker negative group to confidently distinguish between the G-INT and G-DIF cancers. Interestingly, we have also observed that the one-third of 1-marker positive patients also appeared to exhibit an improved survival trend compared to the 2-marker negative group (CDH17, p=0.08 adjusted for stage; LGALS4, p=0.07 adjusted for stage). This result suggests that some of the 1-marker positive cancers may also be G-INT cancers as well (Supplementary Figure S4) . At this stage, it is likely premature to definitely conclude that LGALS4 and CDH17 necessarily represent the best markers for the G-INT subtype. Identifying the optimal combination of immunohistochemical markers to distinguish between the intrinsic subtypes should thus be a focus for future research.
In vitro, G-INT lines were more sensitive to 5-FU and oxaliplatin than G-DIF cell lines, but were also more resistant to cisplatin. Although the absolute magnitude of these in vitro differential sensitivities appears modest (3-5 fold), these differences could still prove clinically meaningful given the relatively small therapeutic windows associated with cytotoxic chemotherapy. Indeed, supporting the clinical relevance of these differences, we observed a significant interaction between the intrinsic subtypes and differential benefit from adjuvant 5-FU therapy in retrospective patient cohorts (Table 3 and Supplementary  Table S4 ). These findings suggest that in addition to patient prognosis, the intrinsic subtypes could potentially be used to guide treatment selection. However, we also emphasize that our results at this stage should be interpreted in the context of an early discovery study, requiring further validation efforts. For example, while we observed a trend of stageadjusted survival benefit in G-INT patients due to 5-FU adjuvant therapy, this benefit was not statistically significant relative to surgery alone (Table 3 (combined, p=0.06) and Supp  Table S4 (gene expression, p=0.18; TMA, p=0.11). There may be multiple reasons for thiscompared to large Phase III trials such as INT-0116 39 , which evaluated adjuvant 5-FU based chemoradiation in GC, our patient cohorts are smaller in size, non-randomized, and being retrospective in nature, quality of surgery and treatment regimens were also not strictly enforced. As such, the interaction of intrinsic subclass with treatment response should definitely be further validated in additional studies (see below). Nevertheless, given the association the intrinsic subtypes with Lauren's, it is worth noting that in INT-0116 40 , a tenyear update subgroup analyses revealed that all GC subsets benefited from 5-FU therapy except for cases with diffuse histology. Moreover, in JCOG 9912 41 which established S-1 monotherapy as a first-line palliative chemotherapy option in Japan, benefit of irinotecan/ cisplatin over 5-FU based monotherapy was observed in diffuse but not intestinal GCs. Our findings in this study are thus consistent with exploratory subgroup analysis of these two large GC clinical trials.
Our hypothesis-generating study requires further validation studies. Most immediately, the interaction between the intrinsic subtypes and treatment outcomes will be retrospectively validated in larger patient cohorts including tissue from a randomized phase 3 Japanese trial in the first line palliative treatment of advanced gastric cancer (PI: Akira Tsuburaya). Future prospective research efforts will focus on validating the predictive value of the GC intrinsic subclasses in the metastatic setting. In most countries, combination therapy with a fluropyrimidine/platinum combination therapy with or without epirubicin remains standard first line palliative chemotherapy(3). We have thus initiated a phase 2 study, Genomic Guided Gastric cancer (3G) trial with mandatory pre-treated tumor biopsies from which patients will be allocated to S1/oxaliplatin or S1/cisplatin based upon their genomic profiles (NCT01100801, http://clinicaltrialsfeeds.org).
In conclusion, the quest for a clinically meaningful GC taxonomy has motivated several attempts to classify GC on the basis of clinical, histologic, and molecular features. With the exception of tumor stage however, few previously-proposed classification strategies have been shown to provide additional prognostic or predictive value. It is possible that the intrinsic subtypes reported here in this study may represent a promising step in establishment of a clinically relevant genomic taxonomy of GC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. 
Clinical Characteristics of Patient Cohorts
Clinical information is available for all but 3 patients in the SG cohort. Median follow-up for patients still alive for the 4 cohorts are 33, 56, 39 and 36 months respectively. 
